{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:02:39Z","timestamp":1792785759859,"version":"4.5.0"},"reference-count":100,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swedish Research Council and the Faculty of Science and Technology","id":[{"id":"https:\/\/ror.org\/03zttf063","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Uppsala University, Uppsala, Sweden","id":[{"id":"https:\/\/ror.org\/048a87296","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monoclonal antibodies (mAbs), engineered to recognize disease-associated antigens, are central to cancer immunotherapy due to their ability to block or eliminate malignant cells by engaging immune effector mechanisms. Yet many tumors evade or suppress these responses, limiting durable clinical benefit and highlighting the need to optimize antibody-based strategies. A critical determinant of mAb activity is antibody isotype, which governs interactions with Fc receptors, complement pathways, and immune effector cells. While most approved therapeutics employ immunoglobulin G1 (IgG1) for its robust immune-stimulating capacity, evidence suggests that context-dependent isotype selection could improve efficacy. Here, we review the structural and functional properties of human IgG and IgA subclasses, with a focus on anti-CD20 rituximab in two- and three-dimensional models of human B-cell lymphoma. We further discuss how antigen density, tumor architecture, and host variables influence antibody-mediated effector functions. Together, these considerations highlight opportunities to refine antibody isotype selection for more individualized cancer immunotherapy.<\/jats:p>\n                  <jats:p>Statement of Significance Antibody isotype is an important but often underexplored determinant of immunotherapy success. Beyond IgG1, subclasses such as IgG3, IgG2, and IgA display distinct functional properties that broaden therapeutic strategies, including agonistic combinations. Integrating insights from advanced 3D tumor models, this review highlights rational, personalized isotype selection to optimize clinical outcomes.<\/jats:p>","DOI":"10.1093\/abt\/tbag032","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:31:31Z","timestamp":1781004691000},"page":"495-507","source":"Crossref","is-referenced-by-count":0,"title":["Why antibody isotype matters for immunotherapy"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9729-2286","authenticated-orcid":false,"given":"Sandra","family":"Kleinau","sequence":"first","affiliation":[{"name":"Department of Cell and Molecular Biology, Uppsala University , 75124 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"2026100105260850300_ref1","doi-asserted-by":"publisher","DOI":"10.3390\/antib8040055","article-title":"Antibody structure and function: the basis for engineering therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"2026100105260850300_ref2","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"2026100105260850300_ref3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41586-020-03144-0","article-title":"IgA transcytosis and antigen recognition govern ovarian cancer immunity","volume":"591","author":"Biswas","year":"2021","journal-title":"Nature"},{"key":"2026100105260850300_ref4","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/mi.2011.39","article-title":"Structure and function relationships in IgA","volume":"4","author":"Woof","year":"2011","journal-title":"Mucosal Immunol"},{"key":"2026100105260850300_ref5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41467-019-13992-8","article-title":"IgA subclasses have different effector functions associated with distinct glycosylation profiles","volume":"11","author":"Steffen","year":"2020","journal-title":"Nat Commun"},{"key":"2026100105260850300_ref6","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"2026100105260850300_ref7","first-page":"279","article-title":"Glycobiology: \u2018the function of sugar in the IgG molecule\u2019","volume":"187","author":"Dwek","year":"1995","journal-title":"J Anat"},{"key":"2026100105260850300_ref8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/jps.23788","article-title":"Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass","volume":"103","author":"Neergaard","year":"2014","journal-title":"J Pharm Sci"},{"key":"2026100105260850300_ref9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4161\/mabs.4.1.18347","article-title":"Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function","volume":"4","author":"Liu","year":"2012","journal-title":"MAbs"},{"key":"2026100105260850300_ref10","doi-asserted-by":"publisher","first-page":"16194","DOI":"10.1074\/jbc.M709987200","article-title":"Human IgG2 antibodies display disulfide-mediated structural isoforms","volume":"283","author":"Wypych","year":"2008","journal-title":"J Biol Chem"},{"key":"2026100105260850300_ref11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ccell.2014.11.001","article-title":"Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies","volume":"27","author":"White","year":"2015","journal-title":"Cancer Cell"},{"key":"2026100105260850300_ref12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.0019-2805.2001.01341.x","article-title":"IgG4 breaking the rules","volume":"105","author":"Aalberse","year":"2002","journal-title":"Immunology"},{"key":"2026100105260850300_ref13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nrd2909","article-title":"Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond","volume":"11","author":"Hogarth","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"2026100105260850300_ref14","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"2026100105260850300_ref15","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.4049\/jimmunol.0902550","article-title":"Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity fc gamma receptor CD32A","volume":"183","author":"Shashidharamurthy","year":"2009","journal-title":"J Immunol"},{"key":"2026100105260850300_ref16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/abt\/tby002","article-title":"Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy","volume":"1","author":"Zahavi","year":"2018","journal-title":"Antib Ther"},{"key":"2026100105260850300_ref17","doi-asserted-by":"publisher","first-page":"1882028","DOI":"10.1080\/19420862.2021.1882028","article-title":"Coming together at the hinges: therapeutic prospects of IgG3","volume":"13","author":"Chu","year":"2021","journal-title":"MAbs"},{"key":"2026100105260850300_ref18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0065-2776(09)03004-1","article-title":"Chapter 4: multitasking by exploitation of intracellular transport functions the many faces of FcRn","volume":"103","author":"Ward","year":"2009","journal-title":"Adv Immunol"},{"key":"2026100105260850300_ref19","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J Immunol"},{"key":"2026100105260850300_ref20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/intimm\/dxl110","article-title":"Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease","volume":"18","author":"Petkova","year":"2006","journal-title":"Int Immunol"},{"key":"2026100105260850300_ref21","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1073\/pnas.74.6.2301","article-title":"Location and structural significance of the oligosaccharides in human Ig-A1 and IgA2 immunoglobulins","volume":"74","author":"Torano","year":"1977","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026100105260850300_ref22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev.immunol.21.120601.141011","article-title":"IgA fc receptors","volume":"21","author":"Monteiro","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"2026100105260850300_ref23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev.immunol.15.1.203","article-title":"Fc receptor biology","volume":"15","author":"Daeron","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"2026100105260850300_ref24","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.4049\/jimmunol.1300261","article-title":"IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fcalpha receptor I","volume":"192","author":"Aleyd","year":"2014","journal-title":"J Immunol"},{"key":"2026100105260850300_ref25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/0008-5472.CAN-15-1232","article-title":"An anti-EGFR IgA that displays improved pharmacokinetics and myeloid effector cell engagement In vivo","volume":"76","author":"Lohse","year":"2016","journal-title":"Cancer Res"},{"key":"2026100105260850300_ref26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"2026100105260850300_ref27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.2787530","article-title":"Monoclonal antibody-mediated tumor regression by induction of apoptosis","volume":"245","author":"Trauth","year":"1989","journal-title":"Science"},{"key":"2026100105260850300_ref28","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"2026100105260850300_ref29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102787118","article-title":"C1q binding to surface-bound IgG is stabilized by C1r(2)s(2) proteases","volume":"118","author":"Zwarthoff","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026100105260850300_ref30","doi-asserted-by":"publisher","first-page":"1795505","DOI":"10.1080\/19420862.2020.1795505","article-title":"Novel chimerized IgA CD20 antibodies: improving neutrophil activation against CD20-positive malignancies","volume":"12","author":"Evers","year":"2020","journal-title":"MAbs"},{"key":"2026100105260850300_ref31","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fimmu.2017.00646","article-title":"Fc-Galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity","volume":"8","author":"Peschke","year":"2017","journal-title":"Front Immunol"},{"key":"2026100105260850300_ref32","doi-asserted-by":"publisher","first-page":"8433","DOI":"10.1073\/pnas.0702936104","article-title":"Agalactosylated IgG antibodies depend on cellular fc receptors for in vivo activity","volume":"104","author":"Nimmerjahn","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026100105260850300_ref33","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3389\/fimmu.2019.01074","article-title":"The role of membrane bound complement regulatory proteins in tumor development and cancer immunotherapy","volume":"10","author":"Geller","year":"2019","journal-title":"Front Immunol"},{"key":"2026100105260850300_ref34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1046\/j.1365-2249.1998.00581.x","article-title":"Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance","volume":"113","author":"Varsano","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"2026100105260850300_ref35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?","volume":"94","author":"Arnould","year":"2006","journal-title":"Br J Cancer"},{"key":"2026100105260850300_ref36","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/eji.202048885","article-title":"Importance of antibody isotypes in antitumor immunity by monocytes and complement using human-immune tumor models","volume":"51","author":"Lara","year":"2021","journal-title":"Eur J Immunol"},{"key":"2026100105260850300_ref37","doi-asserted-by":"publisher","first-page":"19332","DOI":"10.1073\/pnas.1008248107","article-title":"Coordination of fc receptor signaling regulates cellular commitment to phagocytosis","volume":"107","author":"Zhang","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026100105260850300_ref38","doi-asserted-by":"publisher","first-page":"e1008083","DOI":"10.1371\/journal.ppat.1008083","article-title":"Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies","volume":"16","author":"Chu","year":"2020","journal-title":"PLoS Pathog"},{"key":"2026100105260850300_ref39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/sj.bjc.6604812","article-title":"Macrophages and fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40","volume":"100","author":"Oflazoglu","year":"2009","journal-title":"Br J Cancer"},{"key":"2026100105260850300_ref40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006948","article-title":"IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models","volume":"11","author":"Stip","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026100105260850300_ref41","doi-asserted-by":"publisher","first-page":"ltad025","DOI":"10.1093\/immadv\/ltad025","article-title":"Impact of fc receptors and host characteristics on myeloid phagocytic response to rituximab-treated 3D-cultured B-cell lymphoma","volume":"3","author":"Kleinau","year":"2023","journal-title":"Immunother Adv"},{"key":"2026100105260850300_ref42","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/pin.12440","article-title":"Role of tumor-associated macrophages in human malignancies: friend or foe?","volume":"66","author":"Takeya","year":"2016","journal-title":"Pathol Int"},{"key":"2026100105260850300_ref43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4049\/jimmunol.148.1.169","article-title":"Effect of recombinant IFN-gamma (rIFN-gamma) on the mechanism of human macrophage IgG FcRI-mediated cytotoxicity. rIFN-gamma decreases inhibition by cytophilic human IgG and changes the cytolytic mechanism","volume":"148","author":"Van Schie","year":"1992","journal-title":"J Immunol"},{"key":"2026100105260850300_ref44","doi-asserted-by":"publisher","first-page":"113757","DOI":"10.1016\/j.celrep.2024.113757","article-title":"Tissue niche occupancy determines the contribution of fetal- versus bone-marrow-derived macrophages to IgG effector functions","volume":"43","author":"Wohner","year":"2024","journal-title":"Cell Rep"},{"key":"2026100105260850300_ref45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.12703\/P6-13","article-title":"The M1 and M2 paradigm of macrophage activation: time for reassessment","volume":"6","author":"Martinez","year":"2014","journal-title":"F1000Prime Rep"},{"key":"2026100105260850300_ref46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cmi.2014.83","article-title":"The origin and function of tumor-associated macrophages","volume":"12","author":"Liu","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"2026100105260850300_ref47","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","article-title":"Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications","volume":"12","author":"Lin","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2026100105260850300_ref48","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.1038\/ncomms6444","article-title":"Fc gamma receptor-TLR cross-talk elicits pro-inflammatory cytokine production by human M2 macrophages","volume":"5","author":"Vogelpoel","year":"2014","journal-title":"Nat Commun"},{"key":"2026100105260850300_ref49","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00018-018-2976-8","article-title":"The inflammatory function of human IgA","volume":"76","author":"Hansen","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"2026100105260850300_ref50","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2026100105260850300_ref51","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.immuni.2020.07.008","article-title":"CD47 ligation repositions the inhibitory receptor SIRPA to suppress integrin activation and phagocytosis","volume":"53","author":"Morrissey","year":"2020","journal-title":"Immunity"},{"key":"2026100105260850300_ref52","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI81603","article-title":"CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer","volume":"126","author":"Weiskopf","year":"2016","journal-title":"J Clin Invest"},{"key":"2026100105260850300_ref53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026100105260850300_ref54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(21)00338-1","article-title":"Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials","volume":"7","author":"Rubin","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100105260850300_ref55","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1182\/bloodadvances.2021004598","article-title":"The selection of variable regions affects effector mechanisms of IgA antibodies against CD20","volume":"5","author":"Evers","year":"2021","journal-title":"Blood Adv"},{"key":"2026100105260850300_ref56","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of therapeutic antitumor monoclonal antibodies","volume":"81","author":"Tsao","year":"2021","journal-title":"Cancer Res"},{"key":"2026100105260850300_ref57","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"key":"2026100105260850300_ref58","doi-asserted-by":"publisher","first-page":"2310890","DOI":"10.1080\/19420862.2024.2310890","article-title":"Biparatopic antibodies: therapeutic applications and prospects","volume":"16","author":"Niquille","year":"2024","journal-title":"MAbs"},{"key":"2026100105260850300_ref59","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3389\/fonc.2020.01249","article-title":"The latest battles between EGFR monoclonal antibodies and resistant tumor cells","volume":"10","author":"Cai","year":"2020","journal-title":"Front Oncol"},{"key":"2026100105260850300_ref60","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/bs.acr.2020.04.001","article-title":"HER family in cancer progression: from discovery to 2020 and beyond","volume":"147","author":"Kumar","year":"2020","journal-title":"Adv Cancer Res"},{"key":"2026100105260850300_ref61","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"2026100105260850300_ref62","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"2026100105260850300_ref63","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"2026100105260850300_ref64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11523-017-0549-7","article-title":"Immune checkpoint blockade: the new frontier in cancer treatment","volume":"13","author":"Clarke","year":"2018","journal-title":"Target Oncol"},{"key":"2026100105260850300_ref65","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.aller.2018.04.005","article-title":"What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events","volume":"47","author":"Miranda Poma","year":"2019","journal-title":"Allergol Immunopathol (Madr)"},{"key":"2026100105260850300_ref66","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"2026100105260850300_ref67","doi-asserted-by":"publisher","first-page":"18545","DOI":"10.1074\/jbc.M800784200","article-title":"CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins","volume":"283","author":"Polyak","year":"2008","journal-title":"J Biol Chem"},{"key":"2026100105260850300_ref68","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026100105260850300_ref69","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2026100105260850300_ref70","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1084\/jem.20052283","article-title":"Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy","volume":"203","author":"Hamaguchi","year":"2006","journal-title":"J Exp Med"},{"key":"2026100105260850300_ref71","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"2026100105260850300_ref72","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol"},{"key":"2026100105260850300_ref73","doi-asserted-by":"publisher","first-page":"6768","DOI":"10.1038\/s41467-025-61893-w","article-title":"Resolving the structural basis of therapeutic antibody function in cancer immunotherapy with RESI","volume":"16","author":"Pachmayr","year":"2025","journal-title":"Nat Commun"},{"key":"2026100105260850300_ref74","first-page":"5480","article-title":"CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts","volume":"63","author":"Chan","year":"2003","journal-title":"Cancer Res"},{"key":"2026100105260850300_ref75","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41598-021-82841-w","article-title":"Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis","volume":"11","author":"Luo","year":"2021","journal-title":"Sci Rep"},{"key":"2026100105260850300_ref76","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jbiotec.2010.01.012","article-title":"Multicellular tumor spheroids: an underestimated tool is catching up again","volume":"148","author":"Hirschhaeuser","year":"2010","journal-title":"J Biotechnol"},{"key":"2026100105260850300_ref77","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.3389\/fonc.2020.01543","article-title":"Establishment of a 3D Co-culture with MDA-MB-231 breast cancer cell line and patient-derived immune cells for application in the development of immunotherapies","volume":"10","author":"Saraiva","year":"2020","journal-title":"Front Oncol"},{"key":"2026100105260850300_ref78","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1186\/s12885-022-09772-1","article-title":"Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma","volume":"22","author":"Lara","year":"2022","journal-title":"BMC Cancer"},{"key":"2026100105260850300_ref79","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/ijc.2910410324","article-title":"Establishment of a human cell line (mono mac 6) with characteristics of mature monocytes","volume":"41","author":"Ziegler-Heitbrock","year":"1988","journal-title":"Int J Cancer"},{"key":"2026100105260850300_ref80","doi-asserted-by":"publisher","first-page":"102917","DOI":"10.1016\/j.micron.2020.102917","article-title":"X-ray microtomography as a new approach for imaging and analysis of tumor spheroids","volume":"137","author":"Karimi","year":"2020","journal-title":"Micron"},{"key":"2026100105260850300_ref81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040874","article-title":"Organoid and spheroid tumor models: techniques and applications","volume":"13","author":"Gunti","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026100105260850300_ref82","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1182\/blood-2015-09-625343","article-title":"Influence of immunoglobulin isotype on therapeutic antibody function","volume":"127","author":"Beers","year":"2016","journal-title":"Blood"},{"key":"2026100105260850300_ref83","doi-asserted-by":"publisher","first-page":"605231","DOI":"10.3389\/fimmu.2020.605231","article-title":"Developing a 3D B cell lymphoma culture system to model antibody therapy","volume":"11","author":"Foxall","year":"2020","journal-title":"Front Immunol"},{"key":"2026100105260850300_ref84","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.70114","article-title":"Goodbye flat lymphoma biology","volume":"599","author":"Faria","year":"2025","journal-title":"FEBS Lett"},{"key":"2026100105260850300_ref85","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1182\/blood.v98.5.1352","article-title":"Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma","volume":"98","author":"Weng","year":"2001","journal-title":"Blood"},{"key":"2026100105260850300_ref86","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-06-0066","article-title":"Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity","volume":"12","author":"Meerten","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2026100105260850300_ref87","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"2026100105260850300_ref88","doi-asserted-by":"publisher","first-page":"1483617","DOI":"10.3389\/fimmu.2024.1483617","article-title":"Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression","volume":"15","author":"Nguyen","year":"2024","journal-title":"Front Immunol"},{"key":"2026100105260850300_ref89","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1756-8722-5-64","article-title":"Novel CD20 monoclonal antibodies for lymphoma therapy","volume":"5","author":"Cang","year":"2012","journal-title":"J Hematol Oncol"},{"key":"2026100105260850300_ref90","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026100105260850300_ref91","doi-asserted-by":"publisher","first-page":"e92977","DOI":"10.1371\/journal.pone.0092977","article-title":"Phagocytosis via complement or fc-gamma receptors is compromised in monocytes from type 2 diabetes patients with chronic hyperglycemia","volume":"9","author":"Restrepo","year":"2014","journal-title":"PLoS One"},{"key":"2026100105260850300_ref92","doi-asserted-by":"publisher","first-page":"678511","DOI":"10.3389\/fimmu.2021.678511","article-title":"Functional homology for antibody-dependent phagocytosis across humans and rhesus macaques","volume":"12","author":"Pollara","year":"2021","journal-title":"Front Immunol"},{"key":"2026100105260850300_ref93","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026100105260850300_ref94","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/ejh.12839","article-title":"Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response","volume":"98","author":"Marangon","year":"2017","journal-title":"Eur J Haematol"},{"key":"2026100105260850300_ref95","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/BF00916956","article-title":"Evidence that the phagocytosis mediated by the peanut agglutinin-like activity of IgG(fc) receptors of human monocytes is selectively modulated by estradiol and natural estrogens","volume":"8","author":"Malaise","year":"1988","journal-title":"J Clin Immunol"},{"key":"2026100105260850300_ref96","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1556\/030.64.2017.024","article-title":"Is there a hormonal regulation of phagocytosis at unicellular and multicellular levels? A critical review","volume":"64","author":"Csaba","year":"2017","journal-title":"Acta Microbiol Immunol Hung"},{"key":"2026100105260850300_ref97","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng Des Sel"},{"key":"2026100105260850300_ref98","doi-asserted-by":"publisher","first-page":"929895","DOI":"10.3389\/fimmu.2022.929895","article-title":"Role of fc Core Fucosylation in the effector function of IgG1 antibodies","volume":"13","author":"Golay","year":"2022","journal-title":"Front Immunol"},{"key":"2026100105260850300_ref99","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"2026100105260850300_ref100","doi-asserted-by":"publisher","first-page":"105268","DOI":"10.1016\/j.critrevonc.2026.105268","article-title":"Trispecific antibodies: from challenges to integration in cancer therapy","volume":"222","author":"Bahr","year":"2026","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbag032\/68513140\/tbag032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/4\/495\/68513140\/tbag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/4\/495\/68513140\/tbag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:26:18Z","timestamp":1790846778000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/9\/4\/495\/8706337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbag032","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,6,11]]}}}